February 8, 2021 -- Sorrento Therapeutics has formed a subsidiary company called Adnab that will develop and commercialize a Mayo Clinic-developed technology platform for the manufacture of antibody-drug conjugates (ADC), each called an Adnab.
An Adnab is an immune complex of nanoparticle albumin-bound drug products, such as nab-paclitaxel, that are noncovalently conjugated with tumor-targeting monoclonal antibodies (mAbs), the firm said. The products will use Sorrento's G-MAB library of fully humanized mAbs to generate a portfolio of product candidates to target liquid and solid tumors with the potential to treat autoimmune diseases as well.
Dr. Svetomir Markovic, PhD, at the Mayo Clinic spearheads the project, and to date has formed nine potential Adnab candidates, including two that will be investigated in a U.S. Food and Drug Administration (FDA) supervised, investigator-initiated human trial. The company plans to file multiple investigational new drug (IND) applications this year; it also plans to request breakthrough therapy designation from the FDA in both ovarian and endometrial cancers.
Henry Ji, PhD, is Adnab's chairman and CEO.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
